Drug-drug interactions that alter the exposure of glucuronidated drugs: Scope, UDP-glucuronosyltransferase (UGT) enzyme selectivity, mechanisms (inhibition and …
Drug-drug interactions (DDIs) arising from the perturbation of drug metabolising enzyme
activities represent both a clinical problem and a potential economic loss for the …
activities represent both a clinical problem and a potential economic loss for the …
Clinical pharmacokinetics and pharmacodynamics of etravirine: an updated review
JP Havens, AT Podany, KK Scarsi… - Clinical pharmacokinetics, 2020 - Springer
Etravirine is a second-generation non-nucleoside reverse transcriptase inhibitor (NNRTI) for
the treatment of human immunodeficiency virus type 1 infection. It is a potent inhibitor of HIV …
the treatment of human immunodeficiency virus type 1 infection. It is a potent inhibitor of HIV …
Pharmacokinetics of darunavir in fixed‐dose combination with cobicistat compared with coadministration of darunavir and ritonavir as single agents in healthy …
TN Kakuda, M Opsomer, M Timmers… - The Journal of …, 2014 - Wiley Online Library
This study compared the bioavailability of two candidate fixed‐dose combinations (FDCs:
G003 and G004) of darunavir/cobicistat 800/150 mg with that of darunavir 800 mg and …
G003 and G004) of darunavir/cobicistat 800/150 mg with that of darunavir 800 mg and …
Prediction of fetal darunavir exposure by integrating human ex-vivo placental transfer and physiologically based pharmacokinetic modeling
S Schalkwijk, AO Buaben, JJM Freriksen… - Clinical …, 2018 - Springer
Background Fetal antiretroviral exposure is usually derived from the cord-to-maternal
concentration ratio. This static parameter does not provide information on the …
concentration ratio. This static parameter does not provide information on the …
Clinical pharmacology profile of raltegravir, an HIV‐1 integrase strand transfer inhibitor
DM Brainard, LA Wenning, JA Stone… - The Journal of …, 2011 - Wiley Online Library
Raltegravir is an HIV‐1 integrase inhibitor approved to treat HIV infection in adults in
combination with other antiretrovirals. Data from healthy volunteers demonstrate that …
combination with other antiretrovirals. Data from healthy volunteers demonstrate that …
Evaluation of the mean corpuscular volume of peripheral blood mononuclear cells of HIV patients by a coulter counter to determine intracellular drug concentrations
M Simiele, A D'Avolio, L Baietto… - Antimicrobial agents …, 2011 - Am Soc Microbiol
The mean corpuscular volume (MCV) of peripheral blood mononuclear cells (PBMCs) was
determined by Coulter Counter, and data were used to calculate the intracellular drug …
determined by Coulter Counter, and data were used to calculate the intracellular drug …
Quantitation of methotrexate polyglutamates in human whole blood, erythrocytes and leukocytes collected via venepuncture and volumetric absorptive micro-sampling …
DN Daraghmeh, M Moghaddami… - Analytical and …, 2022 - Springer
Low-dose methotrexate (MTX) plays a key role in treatment of rheumatoid arthritis. However,
not all patients respond satisfactorily, and no therapeutic drug monitoring has been …
not all patients respond satisfactorily, and no therapeutic drug monitoring has been …
[HTML][HTML] Computational screening for potential drug candidates against the SARS-CoV-2 main protease
Background: SARS-CoV-2 is the causal agent of the current coronavirus disease 2019
(COVID-19) pandemic. They are enveloped, positive-sense, single-stranded RNA viruses of …
(COVID-19) pandemic. They are enveloped, positive-sense, single-stranded RNA viruses of …
Toward consensus on correct interpretation of protein binding in plasma and other biological matrices for COVID‐19 therapeutic development
M Boffito, DJ Back, C Flexner, P Sjö… - Clinical …, 2021 - Wiley Online Library
The urgent global public health need presented by severe acute respiratory syndrome‐
coronavirus 2 (SARS‐CoV‐2) has brought scientists from diverse backgrounds together in …
coronavirus 2 (SARS‐CoV‐2) has brought scientists from diverse backgrounds together in …
Physiologically based modelling of darunavir/ritonavir pharmacokinetics during pregnancy
A Colbers, R Greupink, C Litjens, D Burger… - Clinical …, 2016 - Springer
Pregnant women are usually excluded from clinical trials. Physiologically based
pharmacokinetic (PBPK) modelling may provide a method to predict pharmacokinetics in …
pharmacokinetic (PBPK) modelling may provide a method to predict pharmacokinetics in …